BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28860824)

  • 21. Decreased expression of RASSF1A tumor suppressor gene is associated with worse prognosis in clear cell renal cell carcinoma.
    Klacz J; Wierzbicki PM; Wronska A; Rybarczyk A; Stanislawowski M; Slebioda T; Olejniczak A; Matuszewski M; Kmiec Z
    Int J Oncol; 2016 Jan; 48(1):55-66. PubMed ID: 26648328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High expression of long noncoding RNA NORAD is associated with poor clinical outcomes in non-M3 acute myeloid leukemia patients.
    Masoud Eslami M; Soufizomorrod M; Ahmadvand M
    Hematol Oncol Stem Cell Ther; 2021 Aug; ():. PubMed ID: 34419481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low Expression of Long Noncoding RNA IRAIN Is Associated with Poor Prognosis in Non-M3 Acute Myeloid Leukemia Patients.
    Pashaiefar H; Izadifard M; Yaghmaie M; Montazeri M; Gheisari E; Ahmadvand M; Momeny M; Ghaffari SH; Kasaeian A; Alimoghaddam K; Ghavamzadeh A
    Genet Test Mol Biomarkers; 2018 May; 22(5):288-294. PubMed ID: 29634410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer.
    Mao WM; Li P; Zheng QQ; Wang CC; Ge MH; Hu FJ; Fang XH; Dong ZM; Ling ZQ
    Arch Med Res; 2011 Apr; 42(3):182-8. PubMed ID: 21722812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients.
    Honda S; Haruta M; Sugawara W; Sasaki F; Ohira M; Matsunaga T; Yamaoka H; Horie H; Ohnuma N; Nakagawara A; Hiyama E; Todo S; Kaneko Y
    Int J Cancer; 2008 Sep; 123(5):1117-25. PubMed ID: 18537155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
    Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
    Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma.
    Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G
    Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
    Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promoter hypermethylation profile of RASSF1A, FHIT, and sFRP1 in intracranial primitive neuroectodermal tumors.
    Chang Q; Pang JC; Li KK; Poon WS; Zhou L; Ng HK
    Hum Pathol; 2005 Dec; 36(12):1265-72. PubMed ID: 16311119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
    Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
    Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
    Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
    Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methylation-independent ITGA2 overexpression is associated with poor prognosis in de novo acute myeloid leukemia.
    Lian XY; Zhang W; Wu DH; Ma JC; Zhou JD; Zhang ZH; Wen XM; Xu ZJ; Lin J; Qian J
    J Cell Physiol; 2018 Dec; 233(12):9584-9593. PubMed ID: 30132837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumourous tissue of breast cancer.
    Yeo W; Wong WL; Wong N; Law BK; Tse GM; Zhong S
    Pathology; 2005 Apr; 37(2):125-30. PubMed ID: 16028839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promoter Methylation of RASSF1A indicates Prognosis for Patients with Stage II and III Colorectal Cancer Treated with Oxaliplatin-Based Chemotherapy.
    Sun X; Yuan W; Hao F; Zhuang W
    Med Sci Monit; 2017 Nov; 23():5389-5395. PubMed ID: 29128865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
    Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
    J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma.
    Tokinaga K; Okuda H; Nomura A; Ashida S; Furihata M; Shuin T
    Oncol Rep; 2004 Oct; 12(4):805-10. PubMed ID: 15375503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
    Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
    J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
    S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors].
    Ma L; Zhang JH; Liu FR; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):657-9. PubMed ID: 16438885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.